about
Neurochemical profile of dementia pugilisticaBACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brainsIncreased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment.Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease.Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort.The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's diseaseSemantic clustering as a neuropsychological predictor for amnestic-MCIDifferences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease.Development and Validation of the Alzheimer's Questionnaire (AQ)Age- and education-adjusted normative data for the Montreal Cognitive Assessment (MoCA) in older adults age 70-99.The diagnostic value of controlled oral word association test-FAS and category fluency in single-domain amnestic mild cognitive impairment.Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairmentValidation and diagnostic accuracy of the Alzheimer's questionnaire.Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementiaArizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Clinical characterization of mild cognitive impairment as a prodrome to dementia with Lewy bodies.Sensitivity to change and prediction of global change for the Alzheimer's QuestionnaireCerebral blood flow in Alzheimer's diseaseBraak staging, plaque pathology, and APOE status in elderly persons without cognitive impairmentComparative analysis of the Alzheimer questionnaire (AQ) with the CDR sum of boxes, MoCA, and MMSE.Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology.Braak stage and trajectory of cognitive decline in noncognitively impaired elders.KIF6 719Arg allele is associated with statin effects on cholesterol levels in amnestic mild cognitive impairment and Alzheimer's disease patients.A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases.Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Patients.Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study.The use of psychometrists in clinical neuropsychology: history, current status, and future directions.Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly.Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease.Molecular and cellular pathophysiology of preclinical Alzheimer's disease.The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment.Description and cohort characterization of the Longevity Study: learning from our elders.Emotional intelligence (EI) as a predictor of depression status in older adults.Age-Associated Alcohol and Driver Risk Differences in Older Adult DUI Offenders.Risk of alcohol abuse in urban versus rural DUI offenders.Longer self-reported sleep duration is associated with decreased performance on the montreal cognitive assessment in older adults.Neuropsychological Correlates of the Alzheimer's Questionnaire.Trajectory and variability characterization of the Montreal cognitive assessment in older adults.
P50
Q28384455-87CAE6CE-1594-41D8-BD0D-2A69CF433188Q33926050-2B1D1B56-F516-4FAB-8634-8C3EF7A70619Q33927061-55F026F5-588D-4995-A7D5-E7960B940CB6Q34150499-A29EC671-3DE5-497C-AC77-9CEA322CD019Q34277495-D904D8A9-D06A-4409-B084-F099E5BAA89FQ34337167-310709AB-1B45-4633-8A42-856983883514Q34714604-26DFAB87-EFA7-43C2-BD4A-74D2DBE153C5Q34970828-5677BC6C-D72D-4EE3-A7FD-29F55CA92FB6Q35557939-A62EF849-CEAD-4AE6-9491-49F165077654Q35580385-BC2593AB-12E8-44AA-91AB-CE28820FAE07Q35622399-2192C4FC-13DE-4107-894F-E3FD969D858CQ35649430-F69D5972-8DD9-4CC5-9175-74981AB73AE4Q35750582-1D83F26A-79FF-4A35-83DE-1D7ACFA8F9ABQ35909622-6585888C-DC32-4457-BE21-C8191672A01FQ35977798-CC82F21E-0646-40CD-8063-E7B8AA4099BDQ36121377-694C3E05-5211-4D28-AC43-36A9D53E6159Q36121420-55FFB88B-C691-4500-A28F-11704C1F14D4Q36298580-E4C78339-793E-4262-9B25-EB6073763DB5Q36349775-F05D16EF-BAB9-4092-A30D-96B986B8E576Q36393028-E7145929-02CC-45E7-80E7-719A83777D63Q36644543-3EB13013-F1CA-4E42-A9B6-2E6E9B20B1AFQ36702235-2F3D1320-9C96-4B30-878F-D6B42257A2ABQ36972872-61F21A95-F534-497E-B6DD-97F0E6E3717BQ37064329-CA8C84BD-62ED-447D-BCA3-6C74C3E9CB5EQ37083632-61BF2ADE-B2FF-42BB-8359-890DD4A056DDQ37199229-491F2D6F-7226-4DFF-BB8F-9690489E52D9Q37448495-7431FFBD-155D-47C4-B367-FC9E9503A980Q37725038-B4FFE1AE-9EE1-474B-94B0-63D988298926Q37990039-B97EE998-11D5-4D4B-BD82-BFB8071C35F9Q38388660-29C8B606-45F8-4031-B0E0-9FEDD18811B6Q38661982-0AA69D0E-FE5E-40EE-BB46-85CBDC029AEFQ38836004-95F43C36-5C8F-4533-B859-3E117F2C3B68Q38926971-55AD68FE-9922-4803-87CD-FE65FF539758Q38942440-6677041A-DDCC-443E-8E20-C8DB81B3288BQ39590494-67BDBDD8-D2CE-4C0C-ABD8-48680EBDD9ECQ40156206-C04E7424-DF3B-46C1-BD2B-6082CDF3BEC8Q40286855-FCCA7ECE-B2CF-42E4-B89B-0B0621175468Q40847567-A526A2D1-F869-4F35-8315-89A234CBC629Q41304045-BF93575C-7311-4E32-BCF7-71A069AB252DQ47393517-D7D2D0D1-FCF8-462E-B6DC-008E96B23EF1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael Malek-Ahmadi
@ast
Michael Malek-Ahmadi
@en
Michael Malek-Ahmadi
@es
Michael Malek-Ahmadi
@nl
type
label
Michael Malek-Ahmadi
@ast
Michael Malek-Ahmadi
@en
Michael Malek-Ahmadi
@es
Michael Malek-Ahmadi
@nl
prefLabel
Michael Malek-Ahmadi
@ast
Michael Malek-Ahmadi
@en
Michael Malek-Ahmadi
@es
Michael Malek-Ahmadi
@nl
P106
P1153
36702958000
P21
P31
P496
0000-0001-9901-3650